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All-trans retinoic acid (ATRA)-induced apoptosis is
preceded by G, arrest in human MCF-7 breast cancer
cells
R Mangiarottil, M Danova2, R Albericil and C Pellicciaril
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Universita e IRCCS Policlinico San Matteo, Piazza Golgi 10, 1-27100, Pavia, Italy
Summary In this study the effects of all-trans retinoic acid (ATRA) on cell cycle and apoptosis of MCF-7 human breast cancer cells were
investigated to elucidate the mechanisms underlying the antineoplastic potential of this retinoid in breast cancer. The antiproliferative effect of
ATRA was evaluated by DNA content measurements and dual-parameter flow cytometry of bromodeoxyuridine (BrdU) incorporation and of
the expression of cell cycle-related proteins (Ki-67 as proliferation marker and statin as quiescence marker) vs DNA content. Apoptosis was
also studied by flow cytometry of either DNA content or Annexin V labelling. After 10-6 M ATRA treatment, the fraction of S-phase cells
decreased significantly, and cells accumulated in the GJG, range of DNA contents. Dual-parameterflow cytograms showed a decrease in the
percentage of Ki-67-labelled cells (after 10 days, only 20% of the cells were still positive for Ki-67 compared with 95% in controls), while the
fraction of statin-positive cells increased slightly. From 3 days of treatment onwards, apoptosis was found to occur. These results show that
ATRA-induced inhibition of MCF-7 cell growth is related to two mechanisms, i.e. the block of cell proliferation, mostly in a pre-S phase, and the
induction of apoptosis. These results should be taken into account when attempting to design treatment programmes that associate ATRA
with antineoplastic compounds of different cell cycle specificity.
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Retinoids are vitamin A analogues that affect growth, maturation
and differentiation of many cell types, both in vivo and in vitro.
They play an important role in the normal processes of develop-
ment and morphogenesis, and in differentiation (De Luca, 1991).
The biological effects ofthese compounds are largely mediated
by specific receptors belonging to the superfamily of nuclear
receptors (Evans, 1988). Three different retinoic acid receptors
(RARs) have so far been identified and they are members of the
steroid/thyroid-hormone/vitamin-D receptor family: RAR alpha
(Giguere et al, 1987), RAR beta (Benbrook et al, 1988) and RAR
gamma (Krust et al, 1989); they all act as ligand-inducible
transcription factors and they activate transcription oftarget genes
after binding to specific retinoic acid-responsive elements
(RAREs) in their promoter.
The retinoids naturally present in mammals exist in the all-
trans, 13-cis or 1 1-cis geometric configurations: in this study the
all-trans retinoic acid (ATRA) was used. ATRA was found to
inhibit growth in a wide variety of normal and tumour cell types
(Lippman et al, 1992) and to sometimes induce cell differentiation
(Fuchs and Green, 1981; Connor, 1986; Kopan et al, 1987).
The growth-inhibitory response to ATRA of human breast
cancer cells such as MCF-7 has been correlated with the presence
offunctional oestrogen receptors (Fontana et al, 1987). This action
is in fact enhanced by the antioestrogen tamoxifen (Fontana,
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1987), but the exact mechanism by which ATRA interferes with
the cell cycle progression of responsive cells has not yet been
completely elucidated (Wicken et al, 1996). It is still unclear
whether the ATRA-induced block in cell growth is due to an arrest
ofcells in the pre-S-phase, the exit ofcells from the cycle into aGo
quiescent state or to cell death via apoptosis.
In an attempt to better understand the mechanism of ATRA
action on cell cycle progression of MCF-7 breast cancer cells,
we undertook a study using multiparameter flow cytometry. The
effect of 1I" M ATRA on cells treated for different times (24 h to
10 days) was assessed first by evaluating DNA content histograms
and then by dual-parameter determination ofeither BrdU incorpo-
ration or immunopositivity for cell-cycle related proteins vs DNA
content. As a markerforproliferating cells, the nuclear antigen Ki-
67 was used (Gerdes et al, 1984), whereas the presence of statin
was considered as an indication of acquired, kinetic quiescence
(Wang, 1985; Wang and Krueger, 1985; Pellicciari et al, 1995).
This approach enables the rapid estimation of the percentage of
actually (or potentially) cycling cells and of quiescent cells
(Pellicciari et al, 1995). To detect apoptotic cells, we assessed the
presence of the sub-G, peak in DNA histograms and the labelling
ofmembrane phosphatidylserine (PS) residues by Annexin V.
MATERIALS AND METHODS
Cell line, culture conditions and drug treatment
Human MCF-7 (oestrogen-dependent mammary carcinoma) cells
were grown in flasks or on glass coverslips in Petri dishes using
Dulbecco's Modified Eagle Medium (DMEM) containing 10%
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Figure I Flow cytometric DNA histograms after propidium iodide staining of MCF-7 cells grown in control medium (A) or in ATRA-containing medium for different durations (B-F 1, 2, 3, 5 and 10 days). The amount of DNA (in abscissa) is expressed in arbitrary units offluorescence intensity. From 2 days onwards, cells with S-phase DNA contents decrease, with a concomitant accumulation of cells in the GJG, range of DNA contents. After 3 days of treatment, asub-Gi apoptotic peak (arrows) became apparent
fetal bovine serum, 2 mm glutamine and 100 units ml-1 each of
streptomycin and penicillin. The medium was removed 24 h after
seeding and replaced either with prewarmed fresh medium
(controls) or with a medium containing 10 M ATRA. Stock solu-
tion of ATRA (10-3 M) in absolute ethanol was stored at -20°C in
the dark and diluted in culture medium to the final working
concentration just before use. Media supplemented with ATRA
were changed every 2 days andcells were allowedto grow from 24
h until 10 days. During treatment, cells were incubated at 37'C in
a fully humidified atmosphere containing 5% carbon dioxide in
the dark. A yellow light source was used during medium changes
to avoid photo-decomposition of the drug. After treatment, cells
grown in flasks were detached by mild trypsinization (0.5% in
phosphate-buffered saline (PBS), containing 0.05% EDTA),
washed with PBS and fixed in suspension with 70% ethanol at4°C
for 30 min before being processed for immunodetection.
Immunofluorescence detection of Ki-67 and statin
Fixed cells were immunoreacted for statin or Ki-67 as reported in
Pellicciari et al (1995, 1996). Anti-Ki-67 monoclonal antibodies
were from Dako (Glostrup, Denmark), while monoclonal anti-
statin antibodies were a kind gift of Dr Eugenia Wang (Wang and
Krueger, 1985). After the incubation with the primary antibodies,
cell samples were incubated with a 1:50 dilution of a fluorescein
isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Sigma
Chemical, St Louis, MO, USA) in PBSFIween/bovine serum
albumin (BSA) solution and finally washed with PBS.
Immunofluorescence detection of BrdU labelling
Control as well as treated MCF-7 cells were pulse labelled for
30 min with 10 gM BrdU (Sigma Chemical); the medium was
washed out and cells were trypsinized and fixed with 70% ethanol
for 30 min at 40C. To detect BrdU-labelled cells, the method
reported in Pellicciari et al (1995) was used. Mouse anti-BrdU
monoclonal antibody was from Becton Dickinson (Mountain
View, CA, USA). Samples were finally reacted for 30 min with a
1:50 dilution in PBS ofan FITC-labelled goatanti-mouseantibody
(Sigma Chemical, St Louis, MO, USA).
Propidium iodide DNA staining of immunolabelled cells
and dual-parameter flow cytometric analyses
After processing for immunofluorescence, cell samples were
counterstained for at least 30 min at room temperature with
5 ,ug ml- propidium iodide (PI) in 0.1 M phosphate buffer pH 7.2,
containing 100 units ml-l RNAase. Bivariate measurements of
green fluorescence (identifying immunolabelled cells) vs red fluo-
rescence (PI-DNA content) were made with a Becton Dickinson
(San Jose, CA, USA) FACStar flow cytometer. This was carried
out under the following conditions: argon ion laser excitation
power 200 mW at 488 nm, 560-nm beam splitter, 510- to 540-nm
band pass filter for the green fluorescence detector and 610-nm
long pass filterforthe redfluorescence detector. The level ofback-
ground fluorescence, because of the non-specific binding of the
FITC-conjugated antibodies, was established using control cell
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Figure 2 Dual-parameter cytograms of DNA content (abscissa) versus
FITC-immunolabelling (ordinate) in control (left column) and 10 days ATRA-
treated (right column) MCF-7 cells. In each column, the graphs for BrdU (A),
Ki-67 (B), and statin (C) immunolabelling are reported. PI-DNA contents and
FITC-immunolabellings are expressed in arbitrary units of fluorescence
intensity. After treatment with ATRA, there was a significant decrease in the
frequency of both S-phase (BrdU-positive) cells and Ki-67 positive cells,
whereas the frequency of statin positive cells increased only slightly
specimens processed as previously described, but either without
incubation with the primary antibodies or with incubation with a
mouse serum containing no specific antigenic activity. The corre-
sponding value of green fluorescence was used as a cut-off value
above which cells were considered as being labelled. Dual-
parameter cytometric data were evaluated with rectangular region
analysis: FITC-immunolabelled cells were those with green fluo-
rescence values exceeding the background threshold determined as
reported above; the ranges for Go-Gi, S- and G2-M phase cells
were established on the basis of the corresponding DNA content
histograms. At least 20 000 cells per sample were considered in
the gated region used for calculations.
80 -
-'
0
'a a1) C.)
0 Q._
0
C
E
E
60
40
20
Ki-67
Statin
0 1 2 3 4 5 6 7
Time of treatment (days)
8 9 10
Figure 3 Changes in the frequency of Ki-67-positive and statin-positive cells
after different times of treatment with ATRA
Flow cytometric analysis of apoptotic cells
DNA content evaluation
For DNA staining and flow cytometric analysis, the single-step
staining procedure previously described by Pellicciari et al (1993)
was used. Either control or ATRA-treated MCF-7 cells were
harvested by mild trypsinization and resuspended in complete
medium (at a final concentration of 106 cells); 1-ml aliquots were
dropped directly into 2 ml of 75 gg ml-1 PI solution in water,
containing 100 units ml-' of RNAase type A (Sigma Chemical),
10 gIM EDTA (to inactivate endogenous endonucleases) and
0.015% Nonidet P40 (Np4O detergent is used here to ensure that
both normal and apoptotic cells can be stained). After 60 min of
staining, cells were analysed with a FACStar flow cytometer, as
reported above. At least 20 000 cells were measured. Values ofPI
fluorescence were presented as DNA histograms, in which
apoptotic cells were identified by the presence of a sub-G, peak.
Labelling with FITC-conjugatedAnnexin V
About 106 cells were labelled for 30 min with FITC-conjugated
Annexin V (Bender Med-Systems, Prodotti Gianni, Italy) in
culture medium (final culture concentration 0.1-1 jig ml-'). Cells
were then counterstained with a 5 jg ml-1 PI solution in the same
medium with no detergent; in these conditions, PI stains necrotic
(or late apoptotic) cells only, while being excluded by intact (both
normal and early apoptotic) cells. Bivariate measurements of green
fluorescence (identifying Annexin-labelled cells) vs red fluores-
cence (identifying cells with damaged membranes) were made
with the FACStar flow cytometer.
RESULTS
DNA content histograms after PI staining are shown in Figure 1.
Starting from 3 days of treatment with ATRA, the frequency of
MCF-7 cells in the S-phase range of DNA content gradually
decreased, and cells accumulated in GIG,. The reduced frequency
of S-phase cells was confirmed by the incorporation of BrdU.
Dual-parameter flow cytograms (Figure 2A) showed a drastic
decrease of labelled cells from about 36% in control to about 7%
after 10 days of treatment.
Cytometric measurements of DNA content vs Ki-67 labelling
(Figure 2B) showed that ATRA had already induced a decrease in
the frequency of labelled cells at 24 h of treatment; by 8-10 days
oftreatment, only 20% ofthe cells were Ki-67 positive (Figure 3).
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Figure 4 Dual-parameter flow cytograms of FITC-labelled Annexin-V (in abscissa) versus PI staining in isotonic conditions (in ordinate) in MCF-7 cells before
(A) and after 1, 2, 3, 5, and 10 days treatment with ATRA (B to F). Normal, non-apoptotic cells were negative for both FITC and PI (quadrant 1); relatively early apoptotic cells were labelled by Annexin V, while being negative for PI (quadrant 2); late apoptotic as well as secondary necrotic cells were labelled both for
Annexin V and PI (quadrant 3). Starting with 3 days treatment, the percentage of apoptotic cells progressively increased (3%, 15%, and 22% at 3, 5 and 10
days, respectively); secondary necrotic cells also increased from about 20 to 30%
The percentage ofstatin-positive cells increased only slightly at
10 days oftreatment with ATRA (about 5%, compared with 2% in
untreated samples; Figure 2C); this suggests that, at the ATRA
concentration used and for the durations of treatment tested, most
of the MCF-7 cells accumulated in the G, phase rather than
entering a quiescentGo state (Figure 3).
Starting from 3 days, a sub-GI peak was found in DNA
histograms (Figure 1), which demonstrates that apoptosis also
occurs.
This cytometric evidence was confirmed by the experiments of
Annexin V labelling (Figure 4). In early stages of apoptosis,
dramatic changes in the organization of plasma membrane take
place, among which is the translocation ofphosphatidylserine (PS)
residues (which, in non-apoptotic cells, lay in the inner phospho-
lipidic leaflet) to the outer surface ofapoptotic cells (Martin et al,
1995). Relatively early apoptotic MCF-7 cells therefore become
positive for Annexin V, while being negative for PI, which is
excluded from the cells; this was apparent in fluorescent and
phase-contrast microscopy (data not shown). Biparametric
cytograms (Figure 4) showed that, starting at 3 days of treatment,
the percentage of apoptotic cells progressively increased (see
legend ofFigure 4), so that at 10 days of treatment the percentage
of dead cells (i.e. apoptotic plus secondary necrotic cells) was
about 50%.
DISCUSSION
It has already beenreported that ATRA is able to induce differenti-
ation both in normal and in malignant cells in culture (Breitman et
al, 1980). Recently, it has been demonstrated that ATRA may have
a strong therapeutic activity in acute promyelocytic leukaemia; its
mechanism primarily relates to the property of determining the
maturation ofthe non-differentiated leukaemic promyelocytes into
non-proliferating, differentiated granulocytes (Huang et al, 1988;
Bollag and Holdener, 1992).
In the rapidly expanding field of clinical oncology, retinoids
have also been indicated as being potentially useful agents in
different solid tumours, such as breast cancer (Warrel, 1994).
ATRA was found to decrease cell growth ofMCF-7 cells (Toma et
al, 1997). This was confirmed in the present paper by cytometric
data, after DNA content evaluation and BrdU vs DNA dual-para-
meter measurements.
Using single-parameter DNA flow cytometry, however, G, and
Go cells cannot be discriminated, and it is therefore unclear
whether the effect of ATRA on cell cycle progression is due to a
lengthening of theG,, pre-DNA synthetic phase and/or to the exit
ofcells from the cycling compartment into an 'out ofcycle' quies-
cent state. The immunolabelling with specific monoclonal anti-
bodies of either the antigen Ki-67 or statin provided the basis
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for a more refined cytometric analysis of the cytokinetic effects
ofATRA.
The flow cytometric study ofcell cycle-related protein vs DNA
content provides new landmarks that can be used to subdivide the
cell cycle into several distinct subcompartments. The antigen Ki-
67 is a non-histone nuclear protein ofunknown function, although
its direct role in the maintenance of cell proliferation has been
demonstrated by the inhibition ofDNA synthesis by specific anti-
sense oligonucleotides for Ki-67 mRNA (Schluter et al, 1993).
This antigen was shown to be absent in Go cells, while being
present in proliferating cells. Ki-67 is expressed at relatively low
levels in GI and early S-phase; it rapidly accumulates during the
second half of S-phase, reaching a peak at GI`M phases and
decreases sharply in post-mitotic cells (Gerdes, 1984; Bruno and
Darzynkiewicz, 1990). Being expressed in all the cycle phases, Ki-
67 is a particularly suitable marker for proliferating cells (Gerdes
et al, 1984; Schluter et al, 1993), and it may therefore be preferred
in cell kinetic studies to other proliferation markers, such as
cyclins, whose expression is limited to well-defined phases or even
subphases ofthe cycle (Gong et al, 1994).
Statin is a 57-kDa envelope-associated nuclear protein
expressed by quiescent cells of normal or tumour origin both in
vivo and in culture (Wang, 1985; Pellicciari et al, 1991; Tsanaclis
et al, 1991; Mitmaker et al, 1993). This protein is present in resting
Go cells, and its expression declines when cells re-enterGI, early
before the transition into S-phase. The immunolabelling with anti-
statin monoclonal antibodies is therefore a unique technique
for identifying quiescent cells by light microscopy or by flow
cytometry, as we recently demonstrated (Pellicciari et al, 1995).
Using these different cell cycle-related proteins as markers of
proliferation potential, we demonstrated that ATRA exerts its
antiproliferative effect on MCF-7 cells in culture by blocking most
of the cells in early G, phase of the cell cycle, a few cells only
entering GO'
Prolonged (at least 3 days) treatment with ATRA may induce
apoptotic cell death in MCF-7 cells; this was confirmed by
labelling with Annexin V. In DNA histograms, the presence of a
sub-G, peak demonstrated thatapoptosis mostly occurred in theG,
phase, although we cannot exclude, based on the present cyto-
metric evidence, that apoptotic death could also take place in other
cell cycle phases. Taken together, these data open interesting
perspectives in the study of the relationship between induction of
quiescence and commitment of apoptosis in response to anti-
neoplastic agents, as it has been recently underlined for retinoic
acid in breast cancer (Liu et al, 1996).
Our results indicating that ATRA-induced growth inhibition is
associated with specific changes in cell cycle progression ofMCF-
7 cells should be taken into account when attempting to design
treatment programmes that associate ATRA with antineoplastic
compounds ofdifferent cell cycle specificity.
ACKNOWLEDGEMENTS
The authors wish to thank Dr Eugenia Wang (The Bloomfield
Centre for Aging, Lady Davis Institute for Medical Research,
Jewish General Hospital, Montreal, Quebec, Canada) for the kind
gift of anti-statin antibody. This study was partly supported by
CNR (ACRO grant 92.02252.PF39), by AIRC and by MURST
(40% and 60%) grants. Thanks are also due to Dr G Dastoli
(Roche, Milan, and G.O.S.R., Study Group for Retinoids in
Oncology) for discussion and continuous support. Flow cytometric
measurements were performed atthe 'Centro Grandi Strumenti' of
the University ofPavia.
REFERENCES
Benbrook P, Lemhardt E and Pfaul M (1988) A new retinoic acid receptor identified
from hepatocarcinoma. Nature 332: 669-672
Bollag W and Holdener EE (1992) Retinoids in cancer prevention and therapy. Ann
Oncol3: 513-526
Breitman TR, Selonick SE and Collins SJ (1980) Induction ofdifferentiation ofthe
human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl
AcadSci USA 77: 2936-2940
Bruno S and Darzynkiewicz Z (1992) Cell cycle dependent expression and stability
ofthe nuclear protein detected by Ki-67 antibody in HL-60 cells. CellProlif
25: 31-40
Connor MJ (1986) Retinoid stimulation ofepidermal differentiation in vivo. Life Sci
38:1807-1812
De Luca CM (1991) Retinoids and their receptors in differentiation, embryogenesis
and neoplasia. FASEB J45: 2924-2933
Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science
240: 889-895
Fontana JA (1987) Interaction ofretinoids and tamoxifen on the inhibition ofhuman
mammary carcinoma cell proliferation. Exp Cell Biol 55: 136-144
Fontana JA, Hiksis G, Miranda DM and Durham JP (1987) Inhibition ofhuman
mammary carcinoma cell proliferation by retinoids and intracellular c-AMP
elevating compounds. JNatl Cancer Inst 78: 1107-1112
Fuchs E and Green H (1981) Regulation ofterminal differentiation ofcultured
human keratinocytes by Vitamin A. Cell 25: 617-625
Gerdes S, Lemke H, Baisch H, Wacker MH, Schwab U and Stein H (1984) Cell
cycle analysis ofa cell-proliferation associated human nuclear antigen defined
by the monoclonal antibody Ki-67. Jlmmunol 133: 1710-1715
Giguere V, Ong ES, Sequi P and Evans RM (1987) Identification of a receptor for
the morphogen retinoic acid. Nature 330: 624-629
Gong J, Li X, Traganos F and Darzynkiewicz Z (1994) Expression ofG1 and G2
cyclins measured in individual cells by multiparameter flow cytometry: a new
tool in the analysis ofthe cell cycle. Cell Prolif27: 357-371
Huang H, Ye Y, Chen S, Chai J, Zhoa L, Gu L and Wang Z (1988) Use ofall-trans
retinoic acid in the treatment ofacute promyelocytic leukemia. Blood72:
567-572
Kopan RG, Trasker G and Fuchs E (1987) Retinoids as important regulators of
terminal differentiation: examining keratin expression in individual epidermal
cells at various stages ofkeratinization. J CellBiol 105: 427-440
Krust A, Kastner P, Petrovich M, Zelent A and Champon P (1989) A third
human retinoic acid receptor, h-RAR gamma. Proc NatlAcadSci USA 86:
5310-5314
Lippman SM, Parkinson DK, Itri LM, Weben RS, Schantw SP, Ota DM,
Schusterman MA, KrakoffRS, Gutterman JU and Hong WK (1992)
13-cis retinoic acid and interferon alfa-2a effective combination therapy
for advanced squamous cell carcinoma ofthe skin. JNatl CancerInst 84:
235-241
Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y, Klaus M, Reed JC and Zhang X
(1996) Retinoic acid receptor beta mediates the growth-inhibitory effect of
retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell
Biol 16: 1138-1149
Martin BS, Reutelingsperger LPM, MC Gahon AJ, Rader JA, Van Schiee RCAA,
La Face DM and Green DR (1995) Early redistribution ofplasma membrane
phosphatidylserine is a general feature ofapoptosis regardless ofthe initiating
stimulus: inhibition by overexpression ofBcl-2 and Abi. JExp Med 182:
1545-1556
Mitmaker B, Bayer I, Bayner S, Gordon PH and Wang E (1993) The differential
expression of statin in the nuclei ofhuman colonic crypts adjacent to a cancer:
an immunohistochemical study. EurJHistochem 37: 43-51
Pellicciari C, Danova M, Giordano M, Furhman Conti AM, Mazzini G, Wang E,
Ronchetti E, Riccardi A and Manfredi Romanini MG (1991) Expression ofcell
cycle related proteins proliferating -cell nuclear antigen (PCNA) and statin-
during adaptation and de-adaptation ofEUE cells to a hypertonic medium. Cell
Prolif24: 469-479
Pellicciari C, Manfredi AA, Bottone MG, Schaack V and Bami S (1993) A single-
step staining procedure for the detection and sorting ofunfixed apoptotic
thymocytes. EurJHistochem 37: 381-390
British Journal ofCancer (1998) 77(2), 186-191 C CancerResearch Campaign 1998Cytokinetic effect ofATRA on MCF-7cells 191
Pellicciari C, Mangiarotti R, Bottone MG, Danova M and Wang E (1995)
Identification ofresting cell by dual parameter flow cytometry ofstatin
expression and DNA content. Cytometry 21: 329-337
Pellicciari C, Bottone MG, Schaack V, Barni S and Manfredi AA (1996)
Spontaneous apoptosis ofthymocytes is uncoupled with progression through
the cell cycle. Exp CellRes 229: 370-377
Schluter C, Duchrow M, Wohlenberg C, Becker MHG, Key G, Flad Hans-D and
Gerder J (1993) The cell proliferation-associated antigen ofantibody Ki-67: a
very large, ubiquitous nuclear protein with numerous repeated elements,
representing a new kind ofcell cycle-maintaining proteins. J CellBiol 123:
513-522
Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardi L, Palumbo R and
Bollag W (1997) Effects ofAll-trans-retinoic acid and 13-cis-retinoic acid on
breast cancer cell lines: growth inhibition and apoptosis induction. IntJ Cancer
70: 1-9
Tsanaclis AM, Brem SS, Gately S, Shipper HM and Wang E (1991) Statin
immunolocalization in human brain tumors. Cancer33: 587-594
Wang E (1985) A 57000 mol wt protein uniquely present in non-proliferating cells
and senescent human fibroblasts. J CellBiol 100: 545-551
Wang E and Krueger JG (1985) Application ofan unique monoclonal antibody as a
marker for non proliferating subpopulations ofcells ofsome tissues.
JHistochem Cytochem 33: 587-594
Warrel Jr R (1994) Applications forretinoids in cancer therapy. Sem Hematol31:
1-13
Wilcken NR, Saracevic B, Musgrave EA and Sutherland RL (1996) Differential
effects ofretinoids and antiestrogens on cell cycle progression and cell cycle
regulatory genes in human breast cancer cells. Cell GrowthDiff7: 65-74
0Cancer Research Campaign 1998 British JournalofCancer(1998) 77(2), 186-191